ArticleScientific reports2025
Evaluation of an experimental therapy based on bovine mesenchymal stem cell (MSC) secretome for the treatment of endometritis in dairy cows.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Puerperium in the Modern Dairy Cow: A Review.Reproduction in domestic animals = Zuchthygiene · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Endometritis impairs uterine function and reduces reproductive performance in dairy cows. Conventional treatment involves intrauterine antibiotics; however, antimicrobial resistance has become an increasing concern worldwide. Biofactors secreted by mesenchymal stem/stromal cells (MSCs), collectively known as the secretome possess immunomodulatory, anti-apoptotic, angiogenic, and antimicrobial properties and may represent a novel alternative for treating bovine endometritis. This study evaluated the in vitro antimicrobial potential of bovine fetal MSC-derived secretome (sMSC) against Escherichia Coli and assessed the safety and efficacy of sMSC-based therapy in dairy cows. Conditioned media (CM) derived from fetal bone marrow (BM) and adipose tissue (AT) MSCs reduced E. Coli survival by up to 98%. Intrauterine administration of sMSC produced no significant clinical or hematological alterations, demonstrating that the treatment is safe. Cows with clinical endometritis receiving two intrauterine doses of lyophilized sMSC, separated by 14 days, showed lower (P < 0.05) endometrial polymorphonuclear (PMN) counts (~ 47%) and postpartum endometritis grade (EG) (~ 78%) than placebo-treated animals (PCB). Proteomic analysis of lyophilized sMSC revealed that 11% of the total protein content corresponded to secreted protein acidic and cysteine rich (SPARC), a molecule with known roles in tissue repair and immune regulation, which may underlie the observed therapeutic effects. Together, these results indicate that bovine sMSC-derived secretome is a safe and effective therapy for treating bovine endometritis, potentially contributing to a reduction in antibiotics use in dairy cows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.